FDA warns of security
flaw in Hospira infusion pumps
Send a link to a friend
[August 01, 2015]
By Jim Finkle
BOSTON (Reuters) - The U.S. Food and Drug
Administration on Friday advised hospitals not to use Hospira Inc's
Symbiq infusion system, saying a security vulnerability could allow
cyber attackers to take remote control of the system.
|
The agency issued the advisory some 10 days after the U.S.
Department of Homeland Security warned of the vulnerability in the
pump, which is used to deliver medications directly into the
bloodstream of patients.
The FDA and DHS cited research from independent cyber security
expert Billy Rios, who found that remote attacks could be launched
on patients by accessing a hospital's network.
Both the FDA and DHS said they know of no cases where such an attack
has been launched, but the FDA said in its advisory that it strongly
encouraged healthcare facilities to stop using the Symbiq infusion
pump system and move to other devices.
"This (vulnerability) could allow an unauthorized user to control
the device and change the dosage the pump delivers, which could lead
to over- or under-infusion of critical patient therapies," the FDA
said in its warning.
It was the first time the FDA has advised healthcare providers to
discontinue use of a medical device because of a cyber-security
vulnerability.
The FDA said Hospira had previously discontinued the manufacture and
sales of the Symbiq system for reasons not related to the cyber
vulnerability, but that they were still in use and being sold by
third parties.
SOFTWARE UPDATE
Hospira said in a notice on its website that it was working with
Symbiq customers to deploy a software update that closes access
ports to the pump and includes other cyber-security protections.
"This option provides our Symbiq customers with another layer of
security for the devices while they remain in the market for another
few months," the statement said.
It said that it was also working with customers of its LifeCare PCA
and Plum A+ infusion devices with advice on how to mitigate
cyber-security vulnerabilities.
FDA spokeswoman Angela Stark said the agency had looked into issues
with other Hospira infusion pumps and issued a safety communication
on two other Hospira models in May.
John Halamka, chief information officer with Boston's Beth Israel
Deaconess Medical Center, said that healthcare providers need to
secure medical devices by putting them behind firewalls and placing
them on private internal networks that are not accessible.
He said that ultimately the responsibility for securing devices lies
with manufacturers.
"They need to re-engineer their devices with security built in," he
said.
[to top of second column] |
PUBLIC SAFETY
The FDA's warning came as industry and government regulators are
placing unprecedented attention on public safety risks posed by
cyber vulnerabilities in products with embedded computers.
Fiat Chrysler last week announced the recall of 1.4 million U.S.
vehicles to install software to prevent hackers from gaining remote
control of the engine, steering and other systems.
It was the first auto recall prompted by a cyber vulnerability.
Critics have warned in recent years that the government is not
moving fast enough to address vulnerabilities in critical
infrastructure, including healthcare and transportation.
A senior Department of Homeland Security official told Reuters in
October that the agency was reviewing about two dozen cases of
possible cyber vulnerabilities in medical devices. He did not
identify the devices under scrutiny, but people familiar with the
agency's work said that they included Hospira pumps.
A DHS spokesman on Friday declined to comment on the status of the
agency's other investigations into medical devices.
Josh Corman, co-founder of the non-profit group I Am The Cavalry,
said the unprecedented responses to Hospira and Fiat Chrysler
vulnerabilities shows that government and industry can find ways to
protect the public from cyber vulnerabilities.
"This is very encouraging," said Corman, whose group lobbies to
boost security of cars and medical devices. "I love this as an
intermediary step while new laws and new regulatory standards are
being developed."
(Additional reporting by Toni Clarke in Washington and Caroline
Humer in New York; Editing by Jonathan Oatis)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |